A Science Immunology study shows how sequential CD40L, IL-4, and IL-21 signaling generates human germinal center B-like cells in vitro—and what the iGCB platform can and cannot model.

Are three batches enough? Explore the process validation lifecycle, PPQ evidence, and continued monitoring through a hypothetical monoclonal antibody program.

Can semaglutide do more than reduce weight? This article examines new mouse evidence linking GLP-1 signaling, calorie restriction, aging biology and healthspan—and what it could mean for human translation and drug development.

Biologics processes continue to evolve after approval. This guide explains how ICH Q12 uses Established Conditions, PACMPs, PLCM documents, and the PQS to make post-approval CMC changes more predictable and risk-based.

A 2026 Science study uses CRISPR TAPIR to increase rRNA transcription and asks whether translation capacity itself can shape stem cell fate, linking ribosome biology with regeneration, ribosomopathies, and cancer.

Biologics quality cannot rely on release testing alone. This guide explains how to build an integrated strategy across materials, manufacturing, analytics, specifications, and continued monitoring.

A practical, end-to-end guide to mRNA-LNP CMC—from templates, IVT mRNA, lipid raw materials, and scale-up to potency, stability, comparability, and current global regulatory expectations.

The bottleneck in In Vivo CAR T may be delivery rather than the CAR itself. This article examines ERTLNP, T-cell activation, mTOR signaling, CMC implications, and the emerging 2026 clinical landscape.

Passing release specifications does not establish comparability. Learn how ICH Q5E integrates risk assessment, analytical characterization, stability, process data, and regulatory strategy.

A biologics specification is not simply a table of tests and limits. This guide explains how ICH Q6B connects product characterization, critical quality attributes, release testing, acceptance criteria, CTD Module 3, and the evolving direction of Q6(R1).

Four ISSCR 2026 keynotes point to one conclusion: gene delivery is the real bottleneck in cell and gene therapy. What it means for CMC, CDMOs, and capital.

Biologics CMC Regulatory Framework: Executive Summary If you only have three minutes, remember these five points: Biologics CMC is not a single regulation. It is a lifecycle framework connecting the product, manufacturing process, analytical methods, control strategy, and pharmaceutical quality system. ICH provides a shared scientific language. FDA and European authorities apply those principles through their own laws, submission pathways, and post-approval change procedures.

Executive Summary If you only have three minutes to read this article, here are five key takeaways: Aging is increasingly viewed as a biological process that can potentially be modified, rather than an inevitable consequence of time. The discovery of the Yamanaka Factors revolutionized modern biology by demonstrating that cell identity is reversible, leading to the development of induced pluripotent stem cells (iPSCs). Today, the most exciting direction in aging research is P

Executive Summary If you only have three minutes to read this article, I hope you'll remember these six things first. The real challenge of Gene Therapy is not just finding the therapeutic gene, but how to safely and effectively deliver the gene into the right cells. AAV (Adeno-associated virus) is one of the most mature in vivo gene delivery platforms currently available. Researchers remove most of the virus's genes, retaining only the structures needed for delivery, and the

Figure 1. Evolution from autologous to off-the-shelf cell therapy. Comparison of autologous and allogeneic cell therapy manufacturing workflows. Unlike patient-specific manufacturing, iPSC-derived allogeneic therapies leverage Master Cell Banks (MCBs), standardized manufacturing processes, and large-scale production to enable scalable, off-the-shelf regenerative medicine. Executive Summary Key Takeaways Induced pluripotent stem cells (iPSCs) have evolved from a stem cell tech

Figure 1. The Journey of Induced Pluripotent Stem Cells (iPSCs): From Somatic Cell Reprogramming to Regenerative Medicine. Adult somatic cells can be reprogrammed into induced pluripotent stem cells (iPSCs), expanded and banked, differentiated into specialized cell types, and applied in disease modeling, drug discovery, regenerative medicine, and cell therapy. This workflow highlights how iPSCs serve as a foundational platform technology connecting basic research with transla

Executive Summary Pfizer has introduced a new platform called USTAT (Unified Sequential Template Amplification and Transcription). The platform uses Rolling Circle Amplification (RCA) to establish an mRNA manufacturing process that does not rely on traditional plasmid DNA. The time from DNA template generation to mRNA production can potentially be reduced to approximately two days. RNA quality approaches that of conventional plasmid DNA-based manufacturing, although challenge

Introduction: For the First Time, Treatment Is About More Than Controlling Blood Sugar For more than a century, the treatment of Type 1 Diabetes (T1D) has been relatively straightforward. If the body cannot produce insulin, we replace insulin. This approach has saved millions of lives since the discovery of insulin in 1921. However, if we look deeper, one important fact becomes apparent: We have never truly addressed the underlying disease. The problem is not simply a lack of

Introduction: Many People Think mRNA Has Already Succeeded — But It’s Just Getting Started Ask most people what mRNA is, and you’ll probably hear answers like: COVID-19 vaccines Moderna Pfizer The breakthrough technology of the pandemic And they wouldn’t be wrong. COVID-19 vaccines represent one of the most successful commercial applications of mRNA technology in history. However, if you ask scientists working in RNA therapeutics, gene therapy, or drug delivery, you may hear

Introduction: The Next Bottleneck in mRNA Therapeutics May Not Be RNA—It May Be the LNP Since the successful launch of COVID-19 mRNA vaccines, mRNA technology has rapidly expanded beyond infectious diseases into areas such as cancer immunotherapy, gene editing, protein replacement therapy, and regenerative medicine. Many scientists believe the next decade will be the golden age of RNA therapeutics. However, anyone who has worked in mRNA drug development quickly realizes a fun